What is Dr. Zubair Khalid's research focus?

Dr. Zubair Khalid specializes in molecular virology, mRNA vaccine development, and computational biology, with a focus on avian pathogens like IBDV and Avian Reovirus.

Where is Dr. Zubair Khalid currently working?

Dr. Zubair Khalid is a Postdoctoral Research Associate at the University of Maryland (UMD), specifically within the Department of Animal and Avian Sciences.

Veterinary Thrombocytopenia: Confirmation, Bleeding Risk, and Diagnostic Workup

At a Glance

Thrombocytopenia is a common laboratory abnormality in veterinary patients that requires systematic confirmation before proceeding with diagnostic workup. The primary clinical concerns are bleeding risk assessment and identification of the underlying cause. This article provides a cross-species approach for veterinarians to confirm thrombocytopenia, evaluate bleeding risk using validated scoring tools, and pursue a structured differential diagnosis.

Clinical Scenario	Initial Action	Bleeding Risk Assessment	Next Diagnostic Step
Incidental low platelet count on CBC, no bleeding signs	Examine blood smear for platelet clumps and estimate platelet count	Low risk if no petechiae, ecchymoses, or mucosal bleeding	Repeat CBC with citrate tube if clumps seen, proceed with history and physical exam
Low platelet count with mild petechiae or ecchymoses	Examine blood smear, assess for pseudothrombocytopenia	Moderate risk, use bleeding score tool if available	Begin diagnostic workup for immune thrombocytopenia or other causes
Low platelet count with active bleeding (epistaxis, melena, hematuria)	Immediate clinical assessment, consider platelet transfusion if severe	High risk, document bleeding sites and severity	Urgent diagnostic workup, consider coagulation testing to rule out DIC

Confirming Thrombocytopenia and Excluding Pseudothrombocytopenia

Blood Smear Examination

The first step after receiving a low platelet count from an automated hematology analyzer is to examine a well-prepared blood smear. Platelet clumps are the most common cause of pseudothrombocytopenia in dogs and cats. Clumps can form during venipuncture, sample handling, or storage. Examine the feathered edge and monolayer of the smear for platelet aggregates. If clumps are present, the automated count may be falsely low. In such cases, estimate the platelet count from the smear by averaging the number of platelets in 10 high-power fields (100x oil immersion) and multiplying by 15,000 to 20,000 per microliter. This estimation is not precise but helps determine if true thrombocytopenia exists.

Repeat Sampling with Citrate Anticoagulant

If platelet clumps are observed on the smear, repeat blood collection using a citrate tube (3.2% sodium citrate) instead of EDTA. Citrate can reduce clumping in some patients. Compare the platelet count from the citrate sample to the original EDTA sample. A significantly higher count in citrate suggests EDTA-induced pseudothrombocytopenia. The Merck Veterinary Manual notes that pseudothrombocytopenia should be suspected when platelet clumps are seen on smear or when the count normalizes with citrate collection.

Clinical Correlation

True thrombocytopenia is more likely when the patient has clinical signs of bleeding, such as petechiae, ecchymoses, epistaxis, gingival bleeding, or melena. However, absence of bleeding does not rule out thrombocytopenia. Many animals with platelet counts between 30,000 and 50,000 per microliter show no spontaneous bleeding. The bleeding risk increases as platelet counts fall below 20,000 to 30,000 per microliter, but individual variation exists. Document the presence or absence of bleeding signs on physical examination.

Bleeding Risk Assessment

Physical Examination Findings

Evaluate the patient for cutaneous and mucosal bleeding. Petechiae are small pinpoint hemorrhages, typically seen on the pinnae, ventral abdomen, mucous membranes, and sclera. Ecchymoses are larger bruise-like areas. Examine the oral cavity for gingival bleeding, the nose for epistaxis, and the eyes for hyphema or retinal hemorrhages. Palpate the abdomen for signs of internal bleeding. Record all findings in the medical record.

Bleeding Score Tools

A validated bleeding score for dogs with immune thrombocytopenia (ITP) has been developed and implemented. This scoring system assigns points based on the severity and location of bleeding. The score helps standardize bleeding assessment and guide treatment decisions. While not universally adopted, using a structured bleeding score improves consistency in clinical evaluation. The ACVIM consensus statement on the diagnosis of immune thrombocytopenia in dogs and cats provides guidance on bleeding assessment.

Coagulation Testing

Thrombocytopenia alone does not cause prolonged prothrombin time (PT) or activated partial thromboplastin time (aPTT). If PT or aPTT is prolonged, consider concurrent coagulopathy such as disseminated intravascular coagulation (DIC), rodenticide toxicity, or liver failure. Perform coagulation testing in patients with severe bleeding or when DIC is suspected. The current diagnostic trends in coagulation disorders among dogs and cats include point-of-care testing and specialized coagulation panels.

Platelet Function Assessment

In patients with suspected platelet dysfunction despite adequate platelet count, consider platelet function testing. However, this is not routinely performed in the initial workup of thrombocytopenia. Focus first on confirming the low count and assessing bleeding risk.

Diagnostic Workup for Underlying Causes

History and Signalment

Obtain a thorough history including recent medications (especially nonsteroidal anti-inflammatory drugs, antibiotics, and vaccines), toxin exposure (rodenticides, onions, garlic, zinc), travel history (vector-borne diseases), and previous medical conditions. Signalment is important: young adult dogs are more likely to have primary immune-mediated thrombocytopenia, while older animals may have neoplasia or chronic disease. Breed predispositions exist for immune-mediated disease in some dog breeds.

Complete Blood Count and Blood Smear

Review the complete blood count for other cell line abnormalities. Anemia may indicate blood loss or hemolysis. Neutropenia or lymphopenia may suggest bone marrow disease or immune-mediated destruction of multiple cell lines. Examine the blood smear for red blood cell morphology (schistocytes suggest microangiopathic hemolysis), white blood cell abnormalities, and platelet morphology (large platelets indicate increased turnover). The presence of large platelets (megathrombocytes) suggests bone marrow regeneration and is more consistent with peripheral destruction than decreased production.

Serum Biochemistry Profile

Perform a serum biochemistry profile to evaluate organ function. Elevated liver enzymes may suggest hepatic disease or lymphoma. Azotemia may indicate renal disease or dehydration. Hyperglobulinemia can occur with chronic infection or neoplasia. Hypoalbuminemia may result from blood loss or chronic disease. Electrolyte abnormalities may provide clues to underlying conditions.

Infectious Disease Testing

Test for vector-borne diseases based on geographic location and travel history. Common pathogens that cause thrombocytopenia include Ehrlichia canis, Anaplasma platys, Babesia species, and Leishmania species. In cats, consider feline leukemia virus (FeLV) and feline immunodeficiency virus (FIV). The World Organisation for Animal Health provides guidelines for animal health and welfare, including infectious disease surveillance.

Immune-Mediated Thrombocytopenia Workup

Primary immune-mediated thrombocytopenia (ITP) is a diagnosis of exclusion. The ACVIM consensus statement on the diagnosis of immune thrombocytopenia in dogs and cats outlines criteria for diagnosis. Key features include severe thrombocytopenia (platelet count less than 30,000 to 50,000 per microliter), presence of large platelets on smear, absence of other causes, and response to immunosuppressive therapy. Anti-platelet antibody testing is available but has limited sensitivity and specificity. The pathophysiology update and diagnostic dilemmas of ITP highlight the challenges in confirming the diagnosis.

Bone Marrow Examination

Bone marrow aspiration or biopsy is indicated when:

Thrombocytopenia is severe and persistent without an identifiable cause
Other cell lines are abnormal (pancytopenia)
There is suspicion of bone marrow neoplasia or myelofibrosis
The patient does not respond to immunosuppressive therapy

Bone marrow examination helps differentiate between decreased platelet production (hypoplasia, aplasia, neoplasia) and increased destruction (megakaryocytic hyperplasia). The Merck Veterinary Manual provides guidance on bone marrow collection and interpretation.

Imaging Studies

Thoracic and abdominal imaging (radiography, ultrasound) may identify underlying neoplasia, lymphadenopathy, splenomegaly, or other abnormalities. Splenic masses, hemangiosarcoma, and lymphoma are common causes of thrombocytopenia in dogs. In cats, consider intestinal histiocytic sarcoma as a rare cause. Imaging is particularly important in older animals or those with unexplained weight loss or organomegaly.

Coagulation Profile

Perform a coagulation profile (PT, aPTT, fibrinogen, D-dimer) when DIC is suspected. DIC can cause thrombocytopenia along with prolonged coagulation times and elevated D-dimer. The current diagnostic trends in coagulation disorders among dogs and cats include point-of-care testing and specialized coagulation panels.

Common Failure Patterns in Diagnostic Workup

Failure to Exclude Pseudothrombocytopenia

The most common error is proceeding with an extensive workup without first confirming true thrombocytopenia. Always examine a blood smear and repeat with citrate if clumps are seen. This simple step can avoid unnecessary testing and treatment.

Overlooking Infectious Causes

In endemic areas, vector-borne diseases are a common cause of thrombocytopenia. Failure to test for Ehrlichia, Anaplasma, Babesia, and Leishmania can lead to misdiagnosis of immune-mediated disease. Geographic history and travel history are essential.

Ignoring Drug History

Many drugs can cause thrombocytopenia through immune-mediated destruction or bone marrow suppression. Common culprits include sulfonamides, cephalosporins, phenobarbital, and chemotherapeutic agents. Obtain a complete medication history including over-the-counter supplements.

Assuming Immune-Mediated Disease Without Exclusion

Primary ITP is a diagnosis of exclusion. Do not assume immune-mediated disease without ruling out infection, neoplasia, and drug reactions. The ACVIM consensus statement emphasizes the importance of a thorough diagnostic workup before initiating immunosuppressive therapy.

Neglecting Bone Marrow Evaluation

In patients with pancytopenia or persistent thrombocytopenia without response to therapy, bone marrow examination is essential. Myelodysplasia, aplastic anemia, and bone marrow neoplasia can present with thrombocytopenia as the initial abnormality.

Records and Measurements

Documentation Requirements

Maintain accurate records of:

Platelet count from automated analyzer and smear estimation
Presence or absence of platelet clumps
Bleeding signs and bleeding score if used
Results of infectious disease testing
Coagulation profile results
Bone marrow examination findings
Response to therapy

Monitoring Parameters

For patients undergoing treatment, monitor:

Platelet count every 24 to 48 hours initially, then weekly until stable
Bleeding signs daily
Adverse effects of therapy (immunosuppressive drugs, transfusions)
Recurrence of thrombocytopenia after tapering therapy

Outcome Measures

Document:

Time to platelet count recovery (platelet count above 50,000 per microliter)
Resolution of bleeding signs
Need for transfusion
Duration of therapy
Relapse rate

Welfare and Safety Context

Bleeding Risk Management

Patients with severe thrombocytopenia (platelet count less than 20,000 per microliter) are at risk for spontaneous bleeding. Minimize stress and handling. Avoid jugular venipuncture if possible. Use minimal restraint. Monitor for signs of internal bleeding such as pale mucous membranes, tachycardia, and weakness.

Transfusion Considerations

Platelet transfusions are indicated for life-threatening bleeding or when surgery is necessary in a thrombocytopenic patient. Fresh whole blood or platelet-rich plasma can be used. However, platelet transfusions have limited availability and short shelf life. The decision to transfuse should be based on clinical bleeding, not platelet count alone.

Zoonotic Considerations

Some causes of thrombocytopenia are zoonotic. Ehrlichiosis, anaplasmosis, babesiosis, and leishmaniasis can be transmitted from animals to humans through vectors. Use appropriate personal protective equipment when handling blood samples. Educate owners about vector control and zoonotic risks.

Prognostic Factors

Prognosis depends on the underlying cause. Primary ITP has a good prognosis with appropriate immunosuppressive therapy, with most dogs achieving remission. Secondary ITP due to infection or neoplasia has a variable prognosis depending on the underlying condition. Bone marrow disorders such as aplastic anemia or myelodysplasia have a guarded prognosis.

Professional Escalation Criteria

Urgent Escalation

Refer to a specialist or emergency facility when:

Platelet count is less than 10,000 per microliter with active bleeding
Patient has severe hemorrhage (epistaxis, melena, hematuria, hyphema)
Patient is unstable (tachycardia, hypotension, pale mucous membranes)
Neurologic signs suggest intracranial bleeding
DIC is suspected

Routine Escalation

Consider referral to a veterinary internist when:

Thrombocytopenia persists despite appropriate therapy
Diagnosis remains unclear after initial workup
Bone marrow examination is needed
Patient requires advanced imaging or specialized testing
Recurrent thrombocytopenia occurs after therapy

Structured Bleeding Risk Scoring and Treatment Triage for Thrombocytopenic Patients

Bleeding Score Implementation for Clinical Decision Making

The development and implementation of a novel immune thrombocytopenia bleeding score for dogs provides a standardized framework for assessing hemorrhage severity and guiding treatment intensity. This scoring system, validated in canine patients, assigns numerical values based on bleeding location, extent, and clinical impact. The bleeding score tool categorizes patients into mild, moderate, or severe bleeding categories, which directly informs whether observation, medical management, or transfusion therapy is indicated.

To implement this scoring system in practice, evaluate the patient systematically across five bleeding domains: cutaneous manifestations, mucosal bleeding, gastrointestinal hemorrhage, urogenital bleeding, and internal or cavity bleeding. Assign points for each domain based on severity. Cutaneous bleeding includes petechiae (1 point for focal, 2 points for generalized), ecchymoses (2 points for single site, 3 points for multiple sites), and hematomas (3 points). Mucosal bleeding encompasses gingival bleeding (1 point for mild, 2 points for spontaneous), epistaxis (2 points for unilateral, 3 points for bilateral or persistent), and ocular bleeding including conjunctival hemorrhage (1 point), hyphema (3 points), or retinal hemorrhage (3 points). Gastrointestinal bleeding presents as melena (2 points), hematochezia (2 points), or hematemesis (3 points). Urogenital bleeding includes hematuria (1 point for microscopic, 2 points for gross) and vaginal or preputial bleeding (2 points). Internal bleeding such as hemothorax, hemoperitoneum, or pulmonary hemorrhage receives 4 points each.

Calculate the total bleeding score by summing points across all domains. A score of 0 to 3 indicates mild bleeding, 4 to 7 indicates moderate bleeding, and 8 or higher indicates severe bleeding. This scoring system correlates with clinical outcomes and helps standardize treatment decisions across different clinicians and institutions. The ACVIM consensus statement on the diagnosis of immune thrombocytopenia in dogs and cats supports the use of structured bleeding assessment in clinical practice.

Treatment Triage Based on Bleeding Score and Platelet Count

Combine the bleeding score with the confirmed platelet count to determine the appropriate treatment intensity. For patients with mild bleeding (score 0 to 3) and platelet counts above 30,000 per microliter, initiate diagnostic workup while providing supportive care. Monitor platelet counts every 24 to 48 hours and reassess bleeding signs daily. These patients rarely require transfusion and may respond to addressing the underlying cause alone.

For patients with moderate bleeding (score 4 to 7) or platelet counts between 10,000 and 30,000 per microliter, initiate immunosuppressive therapy if immune-mediated thrombocytopenia is suspected after excluding infectious causes. The ACVIM consensus statement on the treatment of immune thrombocytopenia in dogs and cats provides guidance on first-line immunosuppressive protocols. Hospitalize these patients for monitoring and administer supportive care including fluid therapy and gastrointestinal protectants if melena or hematochezia is present.

For patients with severe bleeding (score 8 or higher) or platelet counts below 10,000 per microliter, initiate immediate intervention. Consider platelet transfusion using fresh whole blood or platelet-rich plasma if available. Begin immunosuppressive therapy concurrently. These patients require intensive monitoring in a hospital setting with frequent reassessment of bleeding signs and vital parameters. The bleeding score should be repeated every 12 to 24 hours to track response to therapy.

Practical Implementation Steps for Bleeding Score Assessment

Step 1: Perform a complete physical examination with systematic evaluation of all bleeding domains. Use consistent lighting and examine mucous membranes, skin, and visible orifices. Document each finding with specific location and severity descriptors.

Step 2: Assign points for each bleeding domain using the standardized scoring criteria. Record the score in the medical record along with the date and time of assessment. Use a standardized form or template to ensure consistency across examinations.

Step 3: Calculate the total bleeding score and categorize severity as mild, moderate, or severe. Document this category in the medical record and communicate it to the treatment team.

Step 4: Combine the bleeding score with the confirmed platelet count to determine treatment triage category. Use the triage algorithm to guide decisions about hospitalization, transfusion, and immunosuppressive therapy.

Step 5: Reassess the bleeding score at regular intervals. For hospitalized patients, reassess every 12 to 24 hours. For outpatients, reassess at each recheck visit. Document changes in bleeding score and adjust treatment accordingly.

Step 6: Monitor for treatment response by tracking trends in bleeding score and platelet count over time. A decreasing bleeding score with stable or increasing platelet count indicates appropriate response. An increasing bleeding score despite therapy warrants escalation of treatment or further diagnostic investigation.

Record System for Bleeding Score and Treatment Response

Maintain a dedicated record for each thrombocytopenic patient that includes the following elements:

Patient identification: Record patient name, medical record number, species, breed, age, and sex.

Baseline data: Document the initial platelet count from automated analyzer, smear estimation, presence or absence of platelet clumps, and citrate tube count if performed. Record the initial bleeding score with domain-specific point assignments.

Treatment log: Document each treatment administered including drug name, dose, route, frequency, and administration time. Record transfusion details including product type, volume, and any adverse reactions.

Serial assessments: Create a table with columns for date, time, platelet count, bleeding score, bleeding category, treatment administered, and clinician notes. Update this table at each assessment interval.

Outcome measures: Document time to platelet count recovery (defined as platelet count above 50,000 per microliter), time to bleeding score of zero, duration of hospitalization, need for repeat transfusion, and any complications.

Common Failure Patterns in Bleeding Score Implementation

Failure to perform systematic examination: Clinicians may overlook subtle bleeding signs such as conjunctival petechiae or microscopic hematuria. Use a checklist to ensure all domains are evaluated at each assessment.

Inconsistent scoring between clinicians: Different clinicians may assign different scores for the same patient. Provide training on the scoring system and use standardized definitions for each point value. Consider having two clinicians independently score the same patient periodically to assess inter-rater reliability.

Failure to reassess at appropriate intervals: Bleeding status can change rapidly in thrombocytopenic patients. Set specific reassessment intervals based on bleeding severity. Severe cases require more frequent reassessment than mild cases.

Overreliance on platelet count alone: The bleeding score provides clinical context that platelet count alone cannot capture. A patient with a platelet count of 15,000 per microliter but no bleeding signs may require less aggressive intervention than a patient with a platelet count of 30,000 per microliter and active epistaxis. Use both parameters together for treatment decisions.

Neglecting to document bleeding score in medical record: The bleeding score is only useful if it is recorded and accessible to all members of the treatment team. Integrate the score into the medical record system and ensure it is visible during rounds and treatment planning.

Troubleshooting Bleeding Score Discrepancies

When the bleeding score does not match clinical impression, investigate potential causes. If the bleeding score appears lower than expected based on clinical assessment, re-examine the patient systematically to ensure no bleeding domains were missed. Check for internal bleeding that may not be apparent on physical examination. Perform abdominal ultrasound or thoracic radiographs if internal bleeding is suspected.

If the bleeding score appears higher than expected, verify that each point assignment is accurate. Some findings such as mild gingival bleeding after dental examination may be iatrogenic instead of spontaneous. Differentiate between procedure-related bleeding and spontaneous hemorrhage.

When bleeding score and platelet count are discordant, consider platelet function abnormalities. Some patients with adequate platelet counts may have platelet dysfunction due to medications, uremia, or underlying disease. The current diagnostic trends in coagulation disorders among dogs and cats include platelet function testing for such cases.

Welfare and Safety Context for Bleeding Score Implementation

Minimize patient stress during bleeding score assessment. Handle patients gently and use minimal restraint. Perform the examination in a quiet environment with appropriate lighting. For patients with severe thrombocytopenia, avoid jugular venipuncture and use peripheral veins for blood collection. Apply pressure to venipuncture sites for at least 5 minutes to prevent hematoma formation.

Monitor for signs of clinical deterioration during hospitalization. Patients with severe bleeding may develop hypovolemic shock, anemia, or compartment syndrome from large hematomas. Monitor vital parameters including heart rate, respiratory rate, mucous membrane color, capillary refill time, and blood pressure. Document trends in these parameters alongside bleeding score assessments.

Educate owners about bleeding risk and monitoring at home. Provide written instructions for recognizing bleeding signs including petechiae, ecchymoses, epistaxis, melena, hematuria, and hematemesis. Instruct owners to seek immediate veterinary care if bleeding signs worsen or if the patient shows weakness, collapse, or pale mucous membranes.

Professional Escalation Criteria for Bleeding Score

Urgent escalation to emergency or specialty care is indicated when the bleeding score is 8 or higher, when the bleeding score increases by 4 or more points within 24 hours, or when the patient develops new bleeding in a critical site such as the central nervous system, pericardium, or airway. Patients with bleeding scores in the severe category and platelet counts below 10,000 per microliter require immediate specialist consultation.

Routine escalation to a veterinary internist is indicated when the bleeding score remains in the moderate category despite 48 hours of appropriate therapy, when the bleeding score does not decrease by at least 2 points within 72 hours of initiating treatment, or when recurrent bleeding episodes occur after initial improvement. Internists can provide advanced diagnostic testing including bone marrow examination, specialized coagulation panels, and second-line immunosuppressive protocols.

The ACVIM consensus statement on the treatment of immune thrombocytopenia in dogs and cats provides guidance on when to escalate therapy and when to consider referral. Document all escalation decisions and communications with specialists in the medical record.

Structured Diagnostic Algorithm for Thrombocytopenia: Integrating Bleeding Score, Platelet Count, and Treatment Triage

Bleeding Score Implementation for Clinical Decision Making

Treatment Triage Based on Bleeding Score and Platelet Count

Practical Implementation Steps for Bleeding Score Assessment

Step 3: Calculate the total bleeding score and categorize severity as mild, moderate, or severe. Document this category in the medical record and communicate it to the treatment team.

Record System for Bleeding Score and Treatment Response

Maintain a dedicated record for each thrombocytopenic patient that includes the following elements:

Patient identification: Record patient name, medical record number, species, breed, age, and sex.

Common Failure Patterns in Bleeding Score Implementation

Troubleshooting Bleeding Score Discrepancies

Welfare and Safety Context for Bleeding Score Implementation

Professional Escalation Criteria for Bleeding Score

Frequently Asked Questions

What is the most common cause of a falsely low platelet count in veterinary patients?

Platelet clumping during blood collection or sample handling is the most common cause of pseudothrombocytopenia. Examine a blood smear for clumps and repeat sampling with citrate anticoagulant if clumps are present.

How do I estimate platelet count from a blood smear?

Average the number of platelets in 10 high-power fields (100x oil immersion) and multiply by 15,000 to 20,000 per microliter. This estimation is not precise but helps determine if true thrombocytopenia exists.

When should I perform bone marrow examination in a thrombocytopenic patient?

Bone marrow examination is indicated when thrombocytopenia is severe and persistent without an identifiable cause, when other cell lines are abnormal, when bone marrow neoplasia is suspected, or when the patient does not respond to immunosuppressive therapy.

What infectious diseases commonly cause thrombocytopenia in dogs?

Ehrlichia canis, Anaplasma platys, Babesia species, and Leishmania species are common causes. Test based on geographic location and travel history.

Can medications cause thrombocytopenia in dogs and cats?

Yes, many drugs can cause thrombocytopenia through immune-mediated destruction or bone marrow suppression. Common culprits include sulfonamides, cephalosporins, phenobarbital, and chemotherapeutic agents.

What is the bleeding risk for a dog with a platelet count of 30,000 per microliter?

Many animals with platelet counts between 30,000 and 50,000 per microliter show no spontaneous bleeding. However, bleeding risk increases as counts fall below 20,000 to 30,000 per microliter. Individual variation exists.

How do I differentiate primary immune-mediated thrombocytopenia from secondary causes?

Primary ITP is a diagnosis of exclusion. Rule out infection, neoplasia, drug reactions, and other causes before diagnosing primary ITP. The ACVIM consensus statement provides diagnostic criteria.

What is the prognosis for dogs with immune-mediated thrombocytopenia?

Primary ITP has a good prognosis with appropriate immunosuppressive therapy, with most dogs achieving remission. Secondary ITP due to infection or neoplasia has a variable prognosis depending on the underlying condition.

Related Veterinary Guides

References and Further Reading

www.avma.org
www.acvaa.org
Merck Veterinary Manual. Merck Veterinary Manual.
Animal Health and Welfare. World Organisation for Animal Health.
ACVIM consensus statement on the diagnosis of immune thrombocytopenia in dogs and cats.. Journal of veterinary internal medicine, 2024.
ACVIM consensus statement on the treatment of immune thrombocytopenia in dogs and cats.. Journal of veterinary internal medicine, 2024.
Immune thrombocytopenia (ITP): Pathophysiology update and diagnostic dilemmas.. Veterinary clinical pathology, 2019.
Presumed primary immune-mediated neutropenia in 35 dogs: a retrospective study.. The Journal of small animal practice, 2017.
Development and implementation of a novel immune thrombocytopenia bleeding score for dogs.. Journal of veterinary internal medicine, 2018.
Quantitative platelet disorders.. The Veterinary clinics of North America. Small animal practice, 1988.
Case Report: Primary intestinal histiocytic sarcoma in a cat. Frontiers in Veterinary Science, 2026.
Current Diagnostic Trends in Coagulation Disorders Among Dogs and Cats. Veterinary Clinics of North America Small Animal Practice, 2013.

This article is educational and is not a substitute for veterinary diagnosis or treatment. Contact a veterinarian for advice about an individual animal.